Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):438–443. doi: 10.1038/sj.bjc.6690375

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study

S Okada 1, Y Sakata 2, S Matsuno 3, M Kurihara 4, Y Sasaki 5, Y Ohashi 6, T Taguchi 7; for the Cooperative Group of Docetaxel for Pancreatic Cancer in Japan
PMCID: PMC2362341  PMID: 10408850

Abstract

Docetaxel has been reported to show promising anti-tumour activity in pancreatic ductal cancer (PC). This study was conducted to evaluate the activity and toxicity of moderate-dose (60 mg m−2) docetaxel in Japanese chemo-naive patients with measurable metastatic PC. The patients had a performance status of 0–2. They received docetaxel intravenously over a 1- to 2-h period without any premedication for hypersensitivity reactions. This treatment was repeated every 3–4 weeks with dose adjustments based on the toxic effects observed. Twenty-one patients were eligible and treated with docetaxel. The median number of courses was 2 (range, 1–4). None of the patients achieved an objective response; seven showed no change and 13 showed progressive disease. In one patient, the response was not assessable because of early death. The median survival time for all patients was 118 days. The main grade 3–4 toxicities by patient were leucocytopenia (67%) and neutropenia (86%). Other grade 3–4 toxicities included anaemia (10%), thrombocytopenia (5%), nausea/vomiting (29%), anorexia (29%), GOT/GPT increase (10%), alkaline phosphatase increase (14%), malaise/fatigue (33%) and alopecia (24%). In conclusion, docetaxel, administered on this schedule, did not show significant anti-tumour activity in patients with metastatic PC. © 1999 Cancer Research Campaign

Keywords: docetaxel, chemotherapy, pancreatic cancer, phase II study

Full Text

The Full Text of this article is available as a PDF (84.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi I., Watanabe T., Takashima S., Narabayashi M., Horikoshi N., Aoyama H., Taguchi T. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer. 1996 Jan;73(2):210–216. doi: 10.1038/bjc.1996.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bissery M. C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991 Sep 15;51(18):4845–4852. [PubMed] [Google Scholar]
  3. Bissett D., Kaye S. B. Taxol and taxotere--current status and future prospects. Eur J Cancer. 1993;29A(9):1228–1231. doi: 10.1016/0959-8049(93)90062-k. [DOI] [PubMed] [Google Scholar]
  4. Cerny T., Kaplan S., Pavlidis N., Schöffski P., Epelbaum R., van Meerbeek J., Wanders J., Franklin H. R., Kaye S. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer. 1994 Aug;70(2):384–387. doi: 10.1038/bjc.1994.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cortes J. E., Pazdur R. Docetaxel. J Clin Oncol. 1995 Oct;13(10):2643–2655. doi: 10.1200/JCO.1995.13.10.2643. [DOI] [PubMed] [Google Scholar]
  6. Dieras V., Chevallier B., Kerbrat P., Krakowski I., Roche H., Misset J. L., Lentz M. A., Azli N., Murawsky M., Riva A. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer. 1996 Aug;74(4):650–656. doi: 10.1038/bjc.1996.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eisenhauer E. Docetaxel: current status and future prospects. J Clin Oncol. 1995 Dec;13(12):2865–2868. doi: 10.1200/JCO.1995.13.12.2865. [DOI] [PubMed] [Google Scholar]
  8. Fleming T. R. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982 Mar;38(1):143–151. [PubMed] [Google Scholar]
  9. Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M., Hakes T. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994 Nov;12(11):2301–2308. doi: 10.1200/JCO.1994.12.11.2301. [DOI] [PubMed] [Google Scholar]
  10. Guéritte-Voegelein F., Guénard D., Lavelle F., Le Goff M. T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991 Mar;34(3):992–998. doi: 10.1021/jm00107a017. [DOI] [PubMed] [Google Scholar]
  11. Kunitoh H., Watanabe K., Onoshi T., Furuse K., Niitani H., Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996 May;14(5):1649–1655. doi: 10.1200/JCO.1996.14.5.1649. [DOI] [PubMed] [Google Scholar]
  12. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  13. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  14. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
  15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
  16. Taguchi T., Furue H., Niitani H., Ishitani K., Kanamaru R., Hasegawa K., Ariyoshi Y., Noda K., Furuse K., Fukuoka M. [Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug]. Gan To Kagaku Ryoho. 1994 Sep;21(12):1997–2005. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES